Resultats globals: 2 registres trobats en 0.02 segons.
Articles, 2 registres trobats
Articles 2 registres trobats  
1.
11 p, 1.9 MB Many people with chronic lymphocytic leukemia or small lymphocytic lymphoma benefit from ibrutinib treatment up to 8 years : a plain language summary / Barr, Paul M. (University of Rochester Medical Center, USA) ; Owen, Carolyn (University of Calgary, Canada) ; Robak, Tadeusz (Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland) ; Tedeschi, Alessandra (ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy) ; Bairey, Osnat (Rabin Medical Center, Petah Tikva, Israel) ; Burger, Jan A (University of Texas MD Anderson Cancer Center, Houston, USA) ; Hillmen, Peter (The Leeds Teaching Hospitals, St James Institute of Oncology, Leeds, UK) ; Dearden, Claire (The Royal Marsden Hospital, London, UK) ; Grosicki, Sebastian (Silesian Medical University, Katowice, Poland) ; McCarthy, Helen (Royal Bournemouth General Hospital (Dorset, Regne Unit)) ; Li, Jian Yong (Jiangsu Province Hospital, Nanjing, China) ; Offner, Fritz (Universitair Ziekenhuis Gent, Belgium) ; Moreno, Carol (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Jermain, Mandy (Pharmacyclics LLC, an AbbVie Company, South San Francisco, USA) ; Zhou, Cathy (Pharmacyclics LLC, an AbbVie Company, South San Francisco, USA) ; Hsu, Emily (Pharmacyclics LLC, an AbbVie Company, South San Francisco, USA) ; Szoke, Anita (Pharmacyclics LLC, an AbbVie Company, South San Francisco, USA) ; Kipps, Thomas J. (UCSD Moores Cancer Center, San Diego, USA) ; Ghia, Paolo (Università Vita-Salute San Raffaele &IRCCS Ospedale San Raffaele, Milan, Italy)
What is this summary about? This is a plain language summary of a publication describing long-term results from the RESONATE-2 study with up to 8 years of follow-up. The original paper was published in Blood Advances in June 2022. [...]
2022 - 10.2217/fon-2022-0898
Future oncology (London, England), Vol. 18 Núm. 37 (january 2022)  
2.
11 p, 1.4 MB Up to 8-year follow-up from RESONATE-2 : first-line ibrutinib treatment for patients with chronic lymphocytic leukemia / Barr, Paul M. (Clinical Trials Office. Wilmot Cancer Institute. University of Rochester Medical Center) ; Owen, Carolyn (Division of Hematology & Hematological Malignancies. Tom Baker Cancer Centre. University of Calgary) ; Robak, Tadeusz (Medical University of Lodz) ; Tedeschi, Alessandra (Department of Hematology. Azienda Socio Sanitaria Territoriali Grande Ospedale Metropolitano Niguarda) ; Bairey, Osnat (Department of Hematology. Rabin Medical Center) ; Burger, Jan A (Department of Leukemia. University of Texas MD Anderson Cancer Center) ; Hillmen, Peter (Department of Haematology. The Leeds Teaching Hospitals. St. James Institute of Oncology) ; Coutre, Steven E. (Stanford University School of Medicine. Stanford Cancer Cente) ; Dearden, Claire (Haemato-Oncology Department. The Royal Marsden Hospital) ; Grosicki, Sebastian (Department of Hematology and Cancer Prevention. School of Public Health. Silesian Medical University) ; McCarthy, Helen (Royal Bournemouth General Hospital. Haematology Department) ; Li, Jian-Yong (Jiangsu Province Hospital. Department of Hematology) ; Offner, Fritz (Universitair Ziekenhuis Gent. Department of Clinical Hematology) ; Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ; Zhou, Ccathy (Biostatistics. Pharmacyclics LLC. An AbbVie Company) ; Hsu, Emily (Clinical Sciences. Pharmacyclics LLC. An AbbVie Company) ; Szoke, Anita (Clinical Sciences. Pharmacyclics LLC. An AbbVie Company) ; Kipps, Thomas J. (University of California San Diego. Department of Medicine. Moores Cancer Center) ; Ghia, Paolo (Università Vita-Salute San Raffaele. Department of Onco-Hematology. Istituto di Ricovero e Cura a Carattere Scientifico Ospedale San Raffaele) ; Universitat Autònoma de Barcelona
2022 - 10.1182/bloodadvances.2021006434
Blood advances, Vol. 6 Núm. 11 (june 2022) , p. 3440-3450  

Vegeu també: autors amb noms similars
1 Szoke, A.
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.